HIms and Hers shares drop after FDA says Lilly's weight-loss drug not in shortage
Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug regulators said Eli Lilly (NYSE:LLY)'s blockbuster weight-loss and diabetes medications are no longer considered to be in shortage.
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...
Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
The clothing company cut its revenue outlook for the year and said it will again seek to sell its Dockers brand. Shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback